Cyberbiosecurity and Espionage: The Convergence of Biological Risk and Intelligence Operations
In today’s rapidly evolving threat landscape, the once-clear boundaries between scientific innovation, national security, and statecraft are dissolving into a complex and fluid convergence of interests. What was once the exclusive domain of academic research or industrial development is now deeply enmeshed in geopolitical strategy, intelligence operations, and global risk management. Advances in biotechnology, artificial intelligence, and data-driven life sciences no longer exist in isolation, they are shaping, and being shaped by, the strategic objectives of states, the clandestine activities of intelligence agencies, and the risk postures of multinational institutions.
Nowhere is this more evident than in the emerging domain of cyberbiosecurity, a hybrid field that combines digital systems protection with biological risk mitigation.
Espionage has always been concerned with the extraction of valuable or strategic information. In the 21st century, these include biological data, like genomic sequences, proprietary cell lines, vaccine formulations, and synthetic biology algorithms. The stakes are no longer limited to military blueprints or diplomatic communications. Today, the code of life itself is subject to state-level interest, intellectual property theft, and covert manipulation.
Cyberbiosecurity defines the expanding attack surface, an intricate web of digital infrastructure, biological data, automated lab systems, and AI-driven design tools, while espionage supplies the adversarial logic that exploits it with precision and intent. Where cyberbiosecurity exposes the vulnerabilities inherent in the convergence of biology and technology, espionage leverages those vulnerabilities not through random exploitation, but through calculated intelligence objectives: the theft of proprietary research, the manipulation of biological outputs, the silent observation of innovation pipelines, and the erosion of competitive or national advantage through covert means. Together, they form a hybrid threat environment where the adversary is often invisible, the tools are dual-use by nature, and the consequences unfold slowly, yet irreversibly.
At the heart of this convergence is a shift in what constitutes strategic intelligence. As states and non-state actors compete in the biotechnology arms race, the theft of biological intellectual property, especially in genomics, vaccine platforms, AI-driven bioengineering, and pathogen research, has become a high-priority target. This is not merely about economic gain. In certain cases, the objective is to achieve biological parity or superiority, particularly in areas like pandemic response, personalized medicine, or dual-use research. The knowledge itself, how to design, synthesize, or alter living systems, can confer geopolitical advantage. This transforms biotech firms, academic labs, and even hospital networks into espionage targets.
Cyber-espionage in this context follows well-established patterns of covert activity. Advanced Persistent Threat (APT) groups, often operating under state direction or with state tolerance, conduct long-term reconnaissance operations against biotechnology targets. These operations are characterized by stealth, persistence, and complexity. Initial access may be gained through phishing, supply chain compromise, or exploitation of zero-day vulnerabilities in software used for DNA design, lab automation, or data analysis. Once inside, attackers often move laterally within networks, escalating privileges, mapping data flows, and exfiltrating high-value datasets over extended periods. Because these systems are highly specialized, traditional IT monitoring tools often fail to recognize unusual behavior within them, making detection delayed or impossible.
Espionage is not limited to digital infiltration. It includes human intelligence (HUMINT), recruitment of insiders, use of visiting researchers to gain physical or intellectual access, and surveillance of conferences and scientific networks. In many cases, espionage campaigns use a combination of human and technical means: cyber intrusion to gather background data, followed by recruitment efforts based on compromised emails, travel records, or institutional vulnerabilities. For risk and compliance professionals, this raises uncomfortable questions: How well do we know the individuals who have access to our most sensitive biological assets? Are our research collaborations adequately screened for foreign influence or dual-use concerns? Are our export control protocols enforceable in a hybrid threat environment?
One of the unique features of cyberbiosecurity espionage is the difficulty of attribution and the invisibility of consequences. A competitor may use stolen genetic code to reproduce a valuable compound months or years after the breach. A compromised AI model used in synthetic biology may subtly bias research outputs without being recognized. A data leak from a clinical genomics database may only manifest as strategic knowledge in another jurisdiction’s regulatory or healthcare policy. Unlike conventional sabotage or overt theft, espionage in this space is often unacknowledged, and its effects delayed.
This ambiguity creates profound compliance challenges. Organizations must report cyber incidents, yet may not know if data was exfiltrated or merely viewed. They may not be aware of regulatory violations until foreign competitors release products built on their stolen R&D. Worse, many cyberbiosecurity systems integrate AI and open-source components, making attribution and accountability even more difficult. Who is responsible when a machine-learning model trained on compromised data produces a flawed but credible biological output?
To respond to these risks, organizations must incorporate espionage awareness into their governance models, particularly in sectors dealing with sensitive bio-research or dual-use innovation. This includes mapping digital supply chains, conducting background screening of research collaborators, ensuring that AI-based tools have explainability and version control, and adopting advanced threat modeling that accounts for the tactics, techniques, and procedures (TTPs) of state-sponsored threat actors.
The ability to design and manipulate biology is a source of power, and like all sources of power, it attracts covert interest. For legal, risk, and compliance experts, this means reframing how we define security, not as a matter of protecting assets behind firewalls or following protocols, but as a dynamic contest for control over knowledge itself. In this contest, awareness is not enough. Anticipation, coordination, and resilience are now essential pillars of responsible leadership.
Simulating the Unthinkable: A Stress Test
To prepare for the multifaceted threats posed by cyberbiosecurity vulnerabilities, particularly those involving dual-use technologies, organizations should incorporate realistic stress testing exercises. These simulations must expose how the convergence of biological and digital systems could be exploited, and how such an incident would unfold across technical, operational, legal, and reputational domains.
The following scenario is designed specifically for risk, compliance, IT security, security, and laboratory management professionals, and senior leadership. It focuses on the cyber-enabled misuse of dual-use biological capabilities, a growing concern in the biotechnology and synthetic biology sectors.
Stress Test Scenario
Your organization is a biotechnology firm engaged in genome editing research and advanced DNA synthesis services. It holds partnerships with public health authorities, defense agencies, and pharmaceutical companies. The lab operates automated biofoundries, integrated platforms that design, assemble, and synthesize DNA sequences via cloud-connected equipment. The software controlling DNA design and synthesis integrates machine learning to optimize genetic sequences based on uploaded research data. As a dual-use research facility, your organization is subject to national export controls, biosafety regulations, cybersecurity obligations, and contractual confidentiality provisions.
Day 1 – Threat Detection and Initial Response
At 02:37 local time, your security operations center receives a routine alert flagged as low priority by your Security Information and Event Management system. The alert notes an unusual but not unprecedented data exchange between one of your internal AI-assisted sequence design tools and an external IP address. The IP is associated with a widely used cloud services provider in a European jurisdiction known for strict privacy protections. On initial review, the event is logged but not escalated.
By 04:15, however, a threat intelligence platform integrated into your managed detection and response service correlates this low-level anomaly with a broader pattern: the IP address is one node in a concealed VPS chain recently observed in a campaign attributed to an advanced persistent threat group with suspected links to a hostile state actor. The group is known for conducting long-term cyber-espionage operations against critical infrastructure, pharmaceutical research hubs, and national bioeconomy assets. They frequently use nested infrastructure across legal grey zones to obscure command-and-control servers, and they employ obfuscation techniques to mimic traffic from legitimate service providers.
At 05:30, your laboratory automation dashboard shows that three DNA synthesis print jobs were triggered via an API call from your design software. The jobs bypassed manual review due to a fast-track research protocol authorized for trusted internal AI-generated designs. The print orders were processed and shipped overnight to pre-approved partner institutions.
During the first day, upon deeper analysis by your internal threat team, evidence emerges that the compromise did not begin today, but may have originated several weeks ago via a poisoned software update. The attacker appears to have inserted obfuscated code into a third-party machine learning plugin used in your bioinformatics platform, an open-source component integrated into your AI sequence optimization engine. This code remained dormant until triggered by specific parameters likely designed to avoid automated detection and sandboxing environments. Once activated, the malware created covert backdoors and began lateral movement across your network, escalating privileges and silently cataloguing system behavior.
Evidence emerges that during this period the threat actor cloned multiple datasets containing proprietary gene-editing research and uploaded them in fragmented, encrypted form to transient VPS nodes. To further conceal the breach, the exfiltration was timed to coincide with scheduled data synchronization tasks between your cloud environments and academic partners, effectively hiding malicious activity within legitimate research collaboration flows.
Executive Discussion Points:
1. The compromise is not a single event but the culmination of a staged cyber-espionage operation, likely involving months of strategic preparation and insider knowledge of your workflows.
Attribution is difficult; while indicators point to the use of proxy networks and public infrastructure, there is a possibility of a false flag operation or disinformation layer designed to confuse and delay response.
2. The print jobs, though technically authorized, may have been manipulated during the design phase by compromised AI algorithms. This raises immediate dual-use red flags, as the synthesized sequences include elements resembling toxin-producing plasmids, albeit subtly altered to evade existing detection filters.
3. Legal and compliance teams must assess whether the attack constitutes a breach of obligations under national biosafety laws, dual-use export controls, and international treaties, even before the full nature of the synthesized material is confirmed.
4. Communication with external partners, data custodians, and regulators must be carefully coordinated given the sensitivity of the potential data breach, the geopolitical dimension of the threat actor, and the reputational risk to the organization.
Key Tensions Introduced:
Technical vs. Legal Response Timelines: The cybersecurity team needs time to confirm attribution and scope, while legal obligations under data protection and biosecurity law may impose strict deadlines for breach notification.
Attribution Uncertainty: The complexity of the attack infrastructure leaves open the possibility of strategic misdirection by the adversary. How much certainty is required before you name a state actor or raise diplomatic concerns?
Trust in AI Systems: The manipulation of your own AI-driven tools to trigger unauthorized synthesis jobs raises difficult questions about the integrity of automated processes and the governance of human-in-the-loop safeguards.
Export Control Ambiguity: The altered sequences may not meet the threshold of existing export control lists but could be weaponizable. Does your internal review process account for such “grey zone” threats?
This Day 1 scenario sets the stage for a multilayered response that blends cyber forensics, legal crisis management, regulatory navigation, and high-stakes geopolitical considerations. It simulates not only a technical breach but an intelligence operation, testing your organization’s preparedness for the subtleties of modern cyberbiosecurity warfare.
Day 2 – Legal, Regulatory, and Crisis Management Unfolding
By early morning, Day 2, the internal crisis response team is attempting to determine the full legal and regulatory implications of the cyber-intrusion. Initial forensic updates confirm that proprietary AI-assisted gene sequence data was likely altered and then synthesized without human oversight. One of the resulting sequences exhibits characteristics consistent with a known virulence factor, raising the possibility that the attackers deliberately manipulated the synthetic biology tool to produce functionally hazardous biological material.
Legal counsel convenes with the Data Protection Officer, Chief Compliance Officer, and Biosecurity Officer to determine immediate notification obligations. It becomes clear that several conflicting regulatory frameworks are simultaneously in play:
Under data protection laws, if personal genomic data were accessed, either during sequence design or via integration with identifiable patient datasets, the organization may face a strict 72-hour breach notification requirement, with additional disclosures to affected data subjects and supervisory authorities in multiple EU and non-EU jurisdictions.
Under dual-use export control regimes, if the sequence synthesized could be interpreted as having latent military or pathogenic utility, even if it falls outside current control lists, the company may have failed to implement adequate internal compliance programs to prevent unauthorized export of controlled biological knowledge or materials. The overnight shipment to an academic partner abroad, now under quarantine, may constitute a breach, even if carried out automatically.
Under biosafety and biosecurity laws, both national and transnational, the incident could represent an unreported release of sensitive biological material, particularly if the sequence is found to have dual-use potential or is connected to select agent regulations. Depending on the jurisdiction, failure to notify national biosecurity authorities (such as the Bundesamt für Gesundheit in Switzerland or the CDC in the U.S.) could constitute a criminal offense.
Simultaneously, contractual obligations with both private and public stakeholders are under pressure. Several collaboration agreements contain strict clauses on data integrity, biosecurity assurance, and third-party access, any of which may now be in breach. Some partners operate in highly regulated sectors, such as defense, pharmaceuticals, or critical infrastructure, and have "termination for cause" clauses triggered by regulatory investigation or reputational harm.
Complicating matters further, an investigative journalist from a respected international outlet contacts the corporate communications team. The journalist presents detailed knowledge of the breach and alleges that similar vulnerabilities in AI-assisted gene design have been known within the company for over a year, based on an internal reports. This introduces the specter of whistleblower activity, likely from within the research division or IT security team. Crisis PR advisors warn that even a well-managed public statement may not contain the reputational fallout if these claims are substantiated.
The Board of Directors is convened in an emergency session. The General Counsel recommends notifying cybercrime and counterintelligence units at the national level due to the likely involvement of a foreign intelligence-linked APT group. However, senior leadership is hesitant, knowing that escalating the matter to law enforcement or national authorities may lead to seizure of systems, mandatory disclosure of sensitive trade secrets, or the loss of regulatory goodwill.
The Chief Risk Officer presents three near-term scenarios:
1. The sequences prove to be non-pathogenic and of no regulatory interest, but the breach reveals systemic cybersecurity failures.
2. The sequences qualify as dual-use under international guidelines, triggering prolonged regulatory scrutiny and export bans.
3. The sequences are weaponizable, causing cascading criminal, diplomatic, and reputational fallout, including blacklisting, asset freezes, and legal actions across multiple jurisdictions.
Meanwhile, technical teams scramble to verify whether the AI model responsible for gene optimization was fully compromised. There is no guarantee that other, previously generated sequences, currently stored or distributed across a dozen partner labs, are free from similar manipulations. The integrity of past research, some already published and cited, is now in question. The risk extends backward in time, undermining the credibility of the company’s scientific output and its due diligence record.
Emerging Dilemmas:
1. How much information can be shared with partners and regulators without breaching confidentiality agreements or triggering shareholder litigation?
2. Does the organization have a defensible record of AI model governance, or will the compromise of machine-learning algorithms be viewed as a foreseeable risk that was ignored?
3. What is the threshold for declaring a material breach under international export control law when digital-to-biological conversion is involved?
In Day 2 the situation evolves into a full-spectrum crisis management challenge. The intersection of biological risk, legal liability, regulatory exposure, international law, and geopolitical attribution forces the organization to operate in a multidimensional threat environment. Every decision, technical, legal, or strategic, carries implications that extend beyond compliance and into the realm of national security, public health, and corporate survival.
Day 3 – Attribution, Investigation, and Secondary Risks
By Day 3, what began as a suspected cyber-intrusion is now understood to be a deliberate, multi-phase campaign of digital and biological manipulation, with potential roots in a long-term strategy. Forensics confirm that a compromised machine-learning model was used not only to manipulate gene sequence designs during the current breach window but may have been quietly generating vulnerable or malicious biological code for weeks or months, possibly longer. The problem is no longer confined to a single sequence or synthesis job but has become a systemic integrity failure across multiple datasets and research outputs.
Attribution remains technically uncertain and politically sensitive. Indicators continue to point to a specific State-sponsored group, but the group’s infrastructure, built on chained virtual private servers, decentralized command-and-control protocols, and anonymized DNS routing could plausibly be imitated. Attribution confidence is further undermined by the discovery that the group used fragments of code copied from other known threat actors, likely to create a false-flag effect. While your intelligence partners and national cyber response center support the attribution to a state-sponsored actor, your legal team warns that public or official attribution may expose the organization to counter-litigation, diplomatic friction, or retaliatory regulatory scrutiny, especially in countries where the adversary maintains economic influence.
Meanwhile, your internal investigation team, working alongside a contracted digital forensics and incident response provider, uncovers another disturbing dimension: several pieces of compromised firmware were identified within your laboratory’s biofoundry equipment. These devices, used to automate high-throughput DNA assembly, had received firmware updates six months earlier from a third-party supplier, which itself is now under investigation for supply chain vulnerabilities. This raises the specter of a hardware-assisted compromise, expanding the attack surface and casting doubt on the integrity of all laboratory equipment and digital interfaces. Regulatory risk now extends beyond your organization to your entire supplier and partner ecosystem.
As the investigation deepens, your organization faces a dilemma over scope and transparency. On one hand, a narrowly defined narrative, focusing on a one-time breach, isolated sequences, and successful containment, would help contain reputational fallout and preserve commercial relationships. On the other hand, a broader and more honest disclosure may protect the organization legally and ethically in the long run, particularly if further manipulated sequences are discovered later by regulators, researchers, or journalists. However, broader disclosure may also invite shareholder lawsuits, trigger contractual disputes, or even lead to regulatory blacklisting.
Simultaneously, regulatory authorities in multiple jurisdictions begin coordinating an international inquiry. In particular, a European supervisory authority requests a full forensic chain-of-custody review of all sequence design software used in the last six months. A U.S. export control agency demands an immediate halt to all DNA synthesis operations until an internal controls audit confirms full compliance with dual-use mitigation protocols. A Swiss biosecurity regulator initiates a parallel investigation into the possibility of unlicensed handling or production of select agents, depending on the reclassification of the synthesized sequences.
The Board of Directors now requests a full legal and risk analysis regarding potential civil and criminal liabilities. Legal counsel raises the following considerations:
1. Breach of fiduciary duty: If senior leadership ignored previous internal warnings about cyber risks associated with AI-driven biological systems, they may face personal liability under corporate governance law.
2. Negligent failure to prevent foreseeable harm: If the AI models were deployed without adequate oversight, testing, or version control, regulators may characterize this as a systemic failure in governance, not just an operational error.
3. Violation of international treaty obligations: If it is determined that the sequences inadvertently created and exported fall within the scope of the Biological Weapons Convention, even unintentionally, the matter may become the subject of state-level diplomatic engagement or United Nations inquiry.
To complicate matters, insurance coverage disputes emerge. Your cybersecurity policy may not apply in full, as the breach stems in part from compromised firmware and third-party AI plugins, potentially excluded under current clauses. Your directors’ and officers’ (D&O) insurance provider raises preliminary objections to coverage, citing potential “gross negligence” if internal reports had previously flagged software vulnerabilities but were never acted upon.
Simultaneously, reputational damage accelerates. Multiple publications pick up on the incident. One well-respected science journal publishes an editorial questioning the safety of automated synthetic biology platforms, using your organization as a case study. Several of your research collaborators, facing pressure from their own regulators, publicly announce the suspension of all joint projects. A foreign government, citing national security concerns, quietly removes your company from its list of approved biotech vendors.
Secondary risks now emerge:
1. Litigation exposure: Plaintiffs' attorneys are preparing potential class action lawsuits on behalf of research participants whose genomic data may have been exfiltrated or altered. Institutional investors are assessing securities fraud claims related to disclosure obligations.
2. Intellectual property integrity: Your R&D pipeline is now under review, as key innovations may have been built on corrupted or manipulated sequence data. This could invalidate patents or halt regulatory approvals.
3. Regulatory fatigue and paralysis: The volume and variety of overlapping investigations (cyber, export, biosafety, data protection, supply chain) create coordination failures within your organization and overwhelm legal capacity.
By the end of Day 3, it becomes clear that the organization is facing a cascade of interconnected crises that touch every domain of compliance, governance, operations, and diplomacy. The situation demands not only legal containment and incident management, but a fundamental strategic recalibration.
Day 4 and beyond
By Day 4, the crisis has become a multi-theatre, multi-stakeholder engagement, less a discrete incident and more a systemic implosion. The term recovery is proving misleading. There is no system to recover to, no single compromised component to quarantine. The organizational leadership is now confronted with the realization that the breach has transformed the very context in which the company operates, legally, reputationally, and geopolitically.
Internally, the response teams are strained. Legal counsel is working 20-hour days coordinating with outside firms across five jurisdictions. The forensics team is still unable to confirm how many synthesized DNA sequences were generated by the compromised AI models, or how many of those may have been used in research projects, preclinical trials, or therapeutic design pipelines. It is no longer possible to trust the integrity of the data backbone underpinning nearly a year of work.
The Chief Science Officer resigns quietly in the early morning hours, citing personal reasons, but insiders leak to media that she had warned of unchecked algorithmic optimization months ago. Her resignation is followed by a defection: one of the most senior machine learning engineers has accepted a position with a state-funded biotechnology institute in a rival jurisdiction. Intelligence officials express concern: was this recruitment opportunistic, or coordinated?
In the regulatory realm, fractures begin to form. The Swiss authorities demand full digital forensics logs, biosample inventories, and AI model source code. The U.S. Commerce Department, under pressure from Congress, declares your lab infrastructure part of a "dual-use national security interest,” subject to new export restrictions, effectively freezing all transatlantic scientific collaboration until further notice. Meanwhile, your EU-based partners face political pressure not to continue engagement unless the company discloses the full timeline of the breach and its regulatory failures.
Your crisis PR team proposes a public mea culpa. A detailed statement, transparent and humble, would admit the AI system's compromise, highlight your cooperation with regulators, and emphasize your commitment to biosecurity reforms. But this proposal is vetoed at the board level. Several directors, particularly those representing private equity investors, fear that such a statement would open the floodgates to litigation and destroy acquisition value. The impasse leads to a public relations vacuum, and the vacuum is quickly filled by others: journalists, critics, disinformation actors, and competitor narratives.
By late afternoon, you receive word that a hostile nation’s foreign ministry has issued a formal statement accusing your company of biological negligence with potential cross-border impact. This appears to be an opportunistic maneuver, possibly aimed at destabilizing your firm’s partnerships in neutral jurisdictions. But behind the scenes, threat intelligence analysts warn that this public accusation could be a prelude to diplomatic escalation.
Then comes the bombshell: A former employee turned whistleblower testifies that, under pressure to accelerate delivery timelines, safeguards in the AI model governance process were deliberately bypassed. In particular, he alleges that the model’s genetic sequence scoring filter, meant to flag potentially hazardous combinations, was manually overridden in multiple instances, including the design jobs now under regulatory quarantine.
The legal ramifications are immediate:
1. Prosecutors from three countries begin preliminary criminal inquiries into reckless endangerment and criminal negligence under public health and biosafety laws.
2. A parliamentary committee in one jurisdiction subpoenas internal communications from your board and compliance officers.
3. A class action lawsuit is filed on behalf of research subjects whose biospecimens were used in studies now under review due to data integrity failure.
Internally, the once-cohesive leadership begins to fragment. The CTO and CISO argue over responsibility: Was the AI system vulnerable due to insecure deployment, or was the underlying architecture flawed by design? The Board debates whether to restructure the company and spin off the synthetic biology division entirely, perhaps even consider bankruptcy protection for legal containment.
And then, just as the organization prepares for a closed-door strategy retreat, Day 5 begins with a silent escalation: Your monitoring systems detect increased scanning activity against your core infrastructure, originating from multiple networks. The scans are surgical, targeting just the modules related to data integrity verification, incident documentation, and regulatory correspondence. Your team suspects a second wave is coming.
What began as a cyberbiosecurity breach has now become a threat to institutional survival. A second-stage campaign appears imminent, likely aimed at exploiting the legal, operational, and reputational chaos to either finish what the attackers started or to permanently discredit your ability to function in a high-stakes bioeconomy.
The organization stands at a crossroads. Each path carries existential legal, ethical, and geopolitical trade-offs.
Just when we think it can’t get worse, what have we overlooked?
What remains missing from the stress testing exercise is a critical evaluation of espionage and cyber espionage as persistent and strategic threats to the biotechnology sector. While the scenario focuses on the immediate incident response, regulatory exposure, and dual-use implications, it does not fully address the long-term intelligence-gathering operations that may have preceded the breach. Nation-states and well-funded adversaries often engage in extended reconnaissance campaigns, seeding insiders, mapping digital infrastructure, and targeting high-value intellectual property such as proprietary gene sequences, vaccine platforms, or AI-driven biological models. These are not random attacks but part of coordinated efforts to erode technological leadership and gain asymmetric advantage.
A mature stress testing exercise must therefore include threat modeling that anticipates the silent accumulation of knowledge over time, not only the moment of breach. This involves examining, for example:
1. Recruitment risks,
2. Phishing campaigns,
3. Cyber intrusions masked as legitimate collaboration,
4. The targeting of data-rich but lightly defended academic and start-up partners.
Legal, risk, and compliance teams must also consider how to detect, deter, and respond to espionage threats that fall below the threshold of open conflict but have profound national security, economic, and ethical implications. Without integrating these dimensions, any stress test remains incomplete, failing to simulate the invisible yet deliberate strategies that often precede more visible acts of sabotage or theft.
Any good news?
Yes, there is good news. Despite the gravity of hybrid threats like those in the stress test scenario, organizations are not powerless. In fact, many of the cascading failures portrayed in the simulation are preventable through forward-looking governance, rigorous system design, and integrated cross-functional training. The core strength of any organization facing cyberbiosecurity risks is not in eliminating every possible threat, but in anticipating how risks manifest across domains, digital, biological, legal, and organizational, and in building a structure resilient enough to adapt when the unpredictable becomes real.
The good news is that the tools and frameworks needed to anticipate such complex scenarios already exist, and are evolving too, just like threats. Governance models for responsible AI, dual-use screening protocols, and biosafety-compliant lab automation can all be reinforced through internal policy, third-party audits, and threat-informed controls. Proactive engagement with regulators, investment in secure supply chains, and scenario-based legal training help organizations recognize not just the risk landscape, but their own role within it. By rehearsing crisis scenarios, training decision-makers, and treating AI and synthetic biology not as isolated functions but as part of a system of trust, companies can build muscle memory to respond quickly, lawfully, and confidently when anomalies first appear.
Ultimately, the greatest advantage lies in culture, in cultivating a mindset where legal, compliance, scientific, and technical teams collaborate before an incident forces them to. Organizations that invest in interdisciplinary dialogue, implement clear escalation protocols, and simulate regulatory pressure long before a real crisis hits will be the ones that not only survive disruptive events, but emerge stronger, more credible, and more prepared for the bio-digital future. Prevention in cyberbiosecurity isn’t only about better code or stricter labs, it’s about seeing around corners and responding as a unified, strategic enterprise.
From the Paper: "Espionage in Science and Research", from the Bundesamt für Verfassungsschutz (BfV) - the German domestic intelligence service.
Universities and research institutions in Germany are the target of espionage activities emanating from foreign intelligence services. Those services use various methods to get access to information and expertise. The risk of an uncontrolled outflow of expertise can be minimised by implementing and respecting adequate security standards.
Objectives and Implications of Scientific Espionage
- The primary aim of scientific espionage on behalf of foreign states is to acquire information in order to be a step ahead in terms of knowledge or to fill existing gaps in knowledge.
- State-sponsored attackers have extensive personnel and financial resources and operate systematically, skilfully and on a long-term basis.
- They meet with a scientific scene which tends to pay insufficient attention to security aspects and the risk posed by espionage.
Risks
Scientific espionage may have considerable negative implications for the institution:
- loss of orders, patents and profit
- cancellation of joint scientific projects
- loss of confidence and damage to image.
Scientific espionage is also, in the long term, a threat to Germany as an economic and scientific player.
Research areas at particular risk
Certain countries have defined sectors in which they want to achieve a leading role on the world market and/or more independence. The expertise required to that end is obtained by means of both legal and illegal methods.
Various research fields are a special focus of interest.
- Naval architecture and ocean engineering
- Energy saving and electromobility
- Information and communication technologies
- Automation and robotics
- Electricity plants
- Aerospace equipment
- New materials
- Agriculture
- Modern rail transport systems
- Biomedicine and high-performance medical equipment
Scientific Espionage: Modi Operandi and Precautions
In order to gather information, foreign intelligence services use different methods or a combination of them. Scientific institutions need a comprehensive safety concept to protect themselves, which covers the following aspects.
1. Foreign students / Guest scientists
- Foreign intelligence services make use of guest students and guest scientists to gain access to research results.
- Nationals of their country are placed under the obligation to collaborate, are pressurized or are offered baits. Cooperation may also be completely voluntary for patriotic reasons.
- Sometimes existing state affiliations are deliberately concealed from the guest institution.
Example: A guest scientist, specialist field: control engineering, engaged in research at a German university. What he concealed from the university: In his home country, he is the head of a military laboratory for rocket testing.
2. Financing / Joint projects
- Joint research projects and externally financed projects may be exploited by foreign actors to acquire relevant knowledge. Research results may be used in their home country for economic and military purposes.
- In this connection, dual-use goods and/or knowledge of proliferation concern have an important role.
Example: A German university is engaged in research, together with a foreign research institute, on a subject of materials science. The foreign university is known to be close to the military and the research results may find application for ultramodern weapon systems.
Knowledge of proliferation concern is expertise which is required to develop technologies for weapons of mass destruction and delivery systems. Scientific findings often have both civil and military applications. Being aware of this problem is a prerequisite to protecting information of proliferation concern.
3. Cyber attacks
Universities and other research institutions may become the target of state-controlled cyber attacks which are aimed at capturing sensitive research data.
Example: By means of a phishing email, students are directed to the imitated registration page of the university library. The attackers can use the captured access data to penetrate into the computer network.
From the Paper: "Academia as a target. Espionage and proliferation in the academic sector", from the Nachrichtendienst des Bundes (NDB) - the Swiss Federal Intelligence Service.
Raising awareness levels
International collaboration between students and scientists and their ability to move freely and exchange knowledge are of key importance in the research sector and should not be hindered. However, it is vital that universities and research institutes are aware of the threat of espionage and proliferation and take a cautious approach to the handling of critical know-how.
This includes raising awareness and training all staff (scientists, professors, employees, etc.), as well as knowing which technologies are subject to export controls and obtaining export permits from the State Secretariat for Economic Affairs (SECO) where this type of technology is transferred abroad.
Switzerland and the universities and research institutes based here have a responsibility to ensure that the knowledge created or acquired in this country by students and scientists is not misused for illegal purposes. Ignoring the threats associated with this may have serious consequences for an institution if it is actually affected by espionage or proliferation activities.
Possible penalties include the loss of contracts and research funds, exclusion from international research committees, loss of reputation and a lower position in international rankings.
In addition, the outflow of confidential research results abroad could in the long term lead to a deterioration in Switzerland’s international competitiveness in the field of research.
Individuals who conduct espionage on behalf of a foreign intelligence service against Swiss interests are gambling with their future. They risk prison and jeopardise their career.
Open culture
The high technological and academic standards and the openness and welcoming culture of Swiss universities and research institutes are admired worldwide. Here, foreign researchers will find e.g. ultra-modern research laboratories in which they can conduct their scientific experiments.
However, the easy access to buildings, the policy of exchanging scientific information openly, the collaboration with technology companies and the mixture of different nationalities of teaching staff and students also make universities an attractive target for information gathering by foreign intelligence services.
These attempt to gain access to expert opinions or research data on sensitive technologies (e.g. robotics, new materials, nanotechnology) in order to fill knowledge gaps in their countries of origin. This saves the state and its industry research costs, as it is generally more cost-effective to spy on a sought-after technology or product than to invest financial and human resources into one’s own research and development.
Case Study
In 2014, a foreign physicist who was carrying out research at a Dutch University was arrested. He was suspected of having revealed the contents of confidential research to Russia’s Foreign Intelligence Service (SVR).
The physicist had come to the attention of Germany’s Federal Office for the Protection of the Constitution while it was observing a Russian diplomat of the Consulate General in Bonn whom it had uncovered as an SVR officer.
Once a month, the fake diplomat and the physicist would meet in Aachen (Germany), where the diplomat would hand over money to the physicist. Each time, the physicist would drive by car from the Netherlands to Aachen for this meeting.
Following the physicist’s arrest, the University launched an internal investigation and then withdrew his accreditation. The Dutch Ministry of Justice deemed him a ‛danger to the national security of the country’, withdrew his Schengen visa and put out a pronouncement of undesirability.
Collaboration with third parties
Many research institutes engage in collaborative ventures with private companies and government agencies, which also finance relevant research projects. Through such collaborations, the scientists involved in the project gain access to expertise and sensitive information.
In order for companies and authorities to find investments in research worthwhile, they need to be the first to apply the research findings in practice on the market.
If research data and findings are leaked to third parties as a result of an espionage attack, this equates to the theft of financial resources. This jeopardises any future collaboration with the research institute.
The recognition that scientists hope to gain for pioneering research may be denied to them if someone else publishes the research findings or successfully applies them in practice first.
Research
The Swiss Federal Intelligence Service sees applied research in science and technology, such as mechanical engineering, aviation and aerospace technology, electrical engineering, material sciences, chemistry, biology or information technology, as being particularly at risk when it comes to the illegal transfer of knowledge.
However, basic research may also be sensitive where students or scientists learn methods and techniques, which they can either pass on or later misuse for other purposes (dual-use research of concern).
Furthermore, a non-technical field may also attract the interest of a foreign government agency if it involves e.g. political issues which affect the state concerned.
Espionage
Illegal intelligence (espionage) is the procurement of information and data from the political, economic, military, scientific and technological fields, which are passed on, or are intended to be passed on, to a foreign actor (state, group, company, individual, etc.), and used to the detriment of Switzerland, its population or its authorities, companies or institutions.
Case Study
A young scientist at a European university received a contact request from an employee of an Asian think tank via the professional network LinkedIn.
He expressed interest in the scientist’s work and in sharing expertise with the scientist.
The think tank invited the scientist to visit them abroad and offered to cover all his travel and accommodation expenses.
During his stay, the scientist met employees of the think tank, who in reality were state intelligence officers.
The intelligence service then attempted to recruit the scientist as a source, in order to obtain sensitive information from his field of work.
Talent Spotting
Public university events (conferences, seminars, etc.) offer intelligence officers the perfect opportunity to engage in conversation innocuously with the individuals present.
They are interested in experts and will attempt to elicit non-public information (e.g. on current research projects) from them by steering conversations subtly and skilfully. But they will also be on the lookout for individuals with particular political and ideological views as well as for young academics who might have the potential to take up a sensitive post in a government agency or a sensitive role in a high-tech company in the future.
Friendly relationships with these individuals will be cultivated over long periods, with the aim of gaining access to classified information should they be appointed to such posts or roles.
Approaching exchange students
• While establishing a relationship with an exchange student, a foreign intelligence service officer will not admit to being a member of an intelligence service, but will pose e.g. as a student or as a member of a think tank, research or language institute or consultancy firm.
They will contact the student under an innocuous-seeming pretext, such as arranging an interesting job or internship, paid clerical work or a language exchange. The contact will be made either in person or electronically.
Online social networks such as LinkedIn or Facebook, in particular, enable foreign intelligence services to gather information about a targeted individual and to establish initial contact with that person with a view to possible recruitment.
• A foreign intelligence service will ask a student to complete certain tasks or to procure certain information in exchange for payment. This will not necessarily involve sensitive information. The aim is to test the suitability of the person as a potential informant.
• A foreign intelligence service will instruct a professor to recruit foreign students.
• The host country will accuse a student of having committed alleged legal offences or misdemeanours in order to put pressure on this individual and force them into collaborating with the intelligence service.
• Under the pretext of conducting a general survey on a student’s stay in and impressions of the host country (e.g. by means of a questionnaire), the foreign intelligence service will attempt to draw up a profile of a student and to obtain information about their interests, circle of acquaintances or weaknesses.